Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice

被引：29

作者：

Kneepkens, Eva L. ^{[1
]}

Plasencia, Chamaida ^{[2
]}

Krieckaert, Charlotte L. M. ^{[1
]}

Pascual-Salcedo, Dora ^{[3
]}

van der Kleij, Desiree ^{[4
]}

Nurmohamed, Michael T. ^{[1
,5
]}

Teresa Lopez-Casla, M. ^{[2
]}

Wieringa, Roeland ^{[4
]}

Rispens, Theo ^{[6
]}

Wolbink, Gertjan ^{[1
,6
]}

机构：

[1] Jan van Breemen Res Inst Reade, Dept Rheumatol, NL-1056 AB Amsterdam, Netherlands

[2] La Paz Univ Hosp, Dept Rheumatol, Madrid, Spain

[3] La Paz Univ Hosp, Immunol Unit, Madrid, Spain

[4] Sanquin Diagnost Serv, Amsterdam, Netherlands

[5] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands

[6] Univ Amsterdam, Acad Med Ctr, Sanquin Res & Landsteiner Lab, Dept Immunopathol, NL-1105 AZ Amsterdam, Netherlands

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷 / 12期

关键词：

ALPHA MONOCLONAL-ANTIBODY; DOUBLE-BLIND; PHASE-III; IMMUNOGENICITY; METHOTREXATE; EFFICACY; SAFETY;

D O I：

10.1136/annrheumdis-2014-205983

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2217 / U225

页数：3

共 12 条

[1] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[2] Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up [J].

Bartelds, Geertje M. ;

Krieckaert, Charlotte L. M. ;

Nurmohamed, Michael T. ;

van Schouwenburg, Pauline A. ;

Lems, Willem F. ;

Twisk, Jos W. R. ;

Dijkmans, A. C. ;

Aarden, Lucien ;

Wolbink, Gerrit Jan .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (14) :1460-1468

[3] Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis [J].

Emery, Paul ;

Fleischmann, Roy M. ;

Moreland, Larry W. ;

Hsia, Elizabeth C. ;

Strusberg, Ingrid ;

Durez, Patrick ;

Nash, Peter ;

Amante, Eric Jason B. ;

Churchill, Melvin ;

Park, Won ;

Antonio Pons-Estel, Bernardo ;

Doyle, Mittie K. ;

Visvanathan, Sudha ;

Xu, Weichun ;

Rahman, Mahboob U. .

ARTHRITIS AND RHEUMATISM, 2009, 60 (08) :2272-2283

[4] Differential effect of drug interference in immunogenicity assays [J].

Hart, Margreet H. ;

de Vrieze, Henk ;

Wouters, Diana ;

Wolbink, Gerrit-Jan ;

Killestein, Joep ;

de Groot, Els R. ;

Aarden, Lucien A. ;

Rispens, Theo .

JOURNAL OF IMMUNOLOGICAL METHODS, 2011, 372 (1-2) :196-203

[5] Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study (vol 58, pg 964, 2008) [J].

Kay .

ARTHRITIS AND RHEUMATISM, 2010, 62 (11) :3518-3518

[6] Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate [J].

Kay, Jonathan ;

Matteson, Eric L. ;

Dasgupta, Bhaskar ;

Nash, Peter ;

Durez, Patrick ;

Hall, Stephen ;

Hsia, Elizabeth C. ;

Han, John ;

Wagner, Carrie ;

Xu, Zhenhua ;

Visvanathan, Sudha ;

Rahman, Mahboob U. .

ARTHRITIS AND RHEUMATISM, 2008, 58 (04) :964-975

[7] Golimumab, a New Human Anti-Tumor Necrosis Factor α Antibody, Administered Intravenously in Patients With Active Rheumatoid Arthritis Forty-Eight-Week Efficacy and Safety Results of a Phase III Randomized, Double-Blind, Placebo-Controlled Study (vol 62, pg 917, 2010) [J].

Kremer .

ARTHRITIS AND RHEUMATISM, 2010, 62 (10) :3130-3130

[8] Golimumab, a New Human Anti-Tumor Necrosis Factor α Antibody, Administered Intravenously in Patients With Active Rheumatoid Arthritis Forty-Eight-Week Efficacy and Safety Results of a Phase III Randomized, Double-Blind, Placebo-Controlled Study [J].

Kremer, Joel ;

Ritchlin, Christopher ;

Mendelsohn, Alan ;

Baker, Daniel ;

Kim, Lilianne ;

Xu, Zhenhua ;

Han, John ;

Taylor, Peter .

ARTHRITIS AND RHEUMATISM, 2010, 62 (04) :917-928

[9] Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing [J].

Rispens, Theo ;

de Vrieze, Henk ;

de Groot, Els ;

Wouters, Diana ;

Stapel, Steven ;

Wolbink, Gerrit J. ;

Aarden, Lucien A. .

JOURNAL OF IMMUNOLOGICAL METHODS, 2012, 375 (1-2) :93-99

[10] A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach [J].

Schmitz, Susanne ;

Adams, Roisin ;

Walsh, Cathal D. ;

Barry, Michael ;

FitzGerald, Oliver .

ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (02) :225-230

← 1 2 →